Clinical Trial

Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells

Suspended Early Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Modifications to the trial design
Summary
This is an investigator-initiated trial to evaluate the role of anti-CD70-CAR T cells in locally advanced or recurrent/metastatic renal cell carcinoma that is inoperable.
Protocol Amendment History 1 change
critical Recruitment suspended 2026-07-24
Trial Details
NCT Number NCT06586658
Lead Sponsor Shanghai Changzheng Hospital
Collaborators: Shanghai First Song Biotechnology Co., LTD
Conditions Renal Cell Carcinoma
Enrollment 9 participants
Start Date 2024-09-06
Primary Completion 2027-07-16 (estimated)
Study Completion 2027-07-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-23